Asian shares advanced on Tuesday, following U.S. stocks higher after they won back most of losses last week that were capped by a sell-off driven by weak U.S. jobs data. Investors appeared to have recovered some confidence after worries over how President Donald Trump’s tariffs may be punishing the economy sent a shudder through

Viking Therapeutics ' ( VKTX 0.28%) shares could rise over the next year by as much as 165% at the midpoint according to some analysts, or even up to 268% at the high end. The company creates drugs targeting numerous conditions, but its most closely watched and lead candidate is VK2735, a dual GLP-1 and GIP receptor agonist.